Physician

Internal Medicine

Julie Stone is an expert in the field of Internal Medicine. Julie Stone is a published doctor. He published 43 publications, including: 'Single-dose pharmacokinetics of indinavir and the effect of food.' Julie Stone accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• An Integrated Strategy for Implementation of Dried Blood Spots in Clinical Development Programs.
• Medicaid Home and Community-Based Services: How Consumer Access Is Restricted by State Policies.
• A Semi-mechanistic Model for the Effects of a Novel Glucagon Receptor Antagonist on Glucagon and the Interaction Between Glucose, Glucagon, and Insulin Applied to Adap...
• Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics--results from single oral dose studies...
• Pharmacokinetic/pharmacodynamic studies of the 11?-HSD1 inhibitor MK-0916 in healthy subjects.
• Simultaneous Pharmacokinetic Model for Rolofylline and both M1-trans and M1-cis Metabolites.
• Lack of a clinically meaningful pharmacokinetic effect of rifabutin on raltegravir: in vitro/in vivo correlation.
• Population pharmacokinetics and pharmacodynamics of caspofungin in pediatric patients.
• Effect of low-, moderate-, and high-fat meals on raltegravir pharmacokinetics.
• Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants.
• Clinical Pharmacology Profile of Raltegravir, an HIV-1 Integrase Strand Transfer Inhibitor.
• Model-based drug development survey finds pharmacometrics impacting decision making in the pharmaceutical industry.
• Model-based drug development: strengths, weaknesses, opportunities, and threats for broad application of pharmacometrics in drug development.
• Effect of tipranavir-ritonavir on pharmacokinetics of raltegravir.
• Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir.
• Lack of a clinically important effect of moderate hepatic insufficiency and severe renal insufficiency on raltegravir pharmacokinetics.
• Pharmacokinetics and safety of caspofungin in older infants and toddlers.
• Pharmacokinetics and safety of caspofungin in neonates and infants less than 3 months of age.
• Model-based decision making in early clinical development: minimizing the impact of a blood pressure adverse event.
• Effects of omeprazole on plasma levels of raltegravir.
• Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor ralte...
• Minimal effects of ritonavir and efavirenz on the pharmacokinetics of raltegravir.
• Lack of a significant drug interaction between raltegravir and tenofovir.
• Atazanavir modestly increases plasma levels of raltegravir in healthy subjects.
• Lack of a pharmacokinetic effect of raltegravir on midazolam: in vitro/in vivo correlation.
• Single- and multiple-dose administration of caspofungin in patients with hepatic insufficiency: implications for safety and dosing recommendations.
• Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents.
• Hepatic uptake of the novel antifungal agent caspofungin.
• Potential for interactions between caspofungin and nelfinavir or rifampin.
• Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
• Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.
• Implementation of Quantitative and Systems Pharmacology in Large Pharma.
• An LC-MS-MS method for the determination of indinavir, an HIV-1 protease inhibitor, in human plasma.
• Absolute interferometry with a 670-nm external cavity diode laser.
• Characterization of nelfinavir binding to plasma proteins and the lack of drug displacement interactions.
• Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: study design and ...
• Raltegravir thorough QT/QTc study: a single supratherapeutic dose of raltegravir does not prolong the QTcF interval.
• Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms.
• Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug-drug interaction trial design.
• Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women.
• Safety, tolerability, and pharmacokinetics of raltegravir after single and multiple doses in healthy subjects.
• Single-dose pharmacokinetics of indinavir and the effect of food.

Schools

---

• Temple Univ Sch Of Med

Doctors Specialties

---

• Internal Medicine

Accepted Insurances

---

• Personal Choice PPO
• Regional Pref Network EPO
• Regional Pref Network HMO
• Regional Pref Network HMO+
• Regional Pref Network POS+
• Regional Pref Network PPO
• Blue Card PPO
• Community Blue PPO
• Keystone Health Plan East HMO
• MultiPlan PPO
• PHCS Network PPO

Education

---

• San Antonio Uniformed Services Health Education Consortium

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Tresa R. Mascarenhas, MB BS This Doctor is OpenDoctor Recommended.
	Dr. Robert G. Quinton, DO
	Dr. Chia-Shing Yang, MD This Doctor is OpenDoctor Recommended.
	Dr. Nirmol M. Philip, MD
	Dr. Janis S. Lawrence-Jackson, DO This Doctor is OpenDoctor Recommended.
	Dr. Leroi S. Hicks, MD
	Dr. Mireille P. Aujero, MD This Doctor is OpenDoctor Recommended.
	Dr. Edward J. McConnell III, MD This Doctor is OpenDoctor Recommended.
	Dr. Heather E. Ragozine-Bush, MD This Doctor is OpenDoctor Recommended.
	Dr. Jaya D. Bathina, MD
	Dr. Ashish Khandelwal, MD This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog